Vorinostat enhances the therapeutic potential of Erlotinib via MAPK in lung cancer cells

Vorinostat enhances the therapeutic potential of Erlotinib via MAPK in lung cancer cells

Background: Lung cancer is the second most common cancer in both men and women, with an estimated 235,760 new cases and 131,880 deaths in 2021 in the US. Despite the modern therapies being available such as radiotherapy and chemotherapy, death rates are still increasing. Erlotinib (ERL) is one of th...

Full description

Bibliographic Details
Main Authors: Amany I Alqosaibi, Shaimaa Abdel-Ghany, Fatma Al-Mulhim, Hussein Sabit
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:Cancer Treatment and Research Communications
Subjects:
Lung cancer
Erlotinib
ERL
SAHA
Vorinostat
MAPK
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294222000016

Similar Items

Similar Items